American College of Cardiology/American Heart Association Task Force on Practice Guidelines

American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Name	American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Formation	20th century
Headquarters	Washington, D.C.
Leader title	Chair
Leader name	Eugene Braunwald
Website	Official site

American College of Cardiology/American Heart Association Task Force on Practice Guidelines is a joint committee formed to produce clinical practice guidelines that inform cardiovascular care across United States, Canada, United Kingdom, Germany, and other international settings. The Task Force collaborates with specialty societies such as the European Society of Cardiology, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, American College of Physicians, and patient advocacy organizations including American Heart Association affiliates and the National Institutes of Health. Its outputs influence policy in institutions like Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and academic centers such as Harvard Medical School and Stanford University School of Medicine.

History and formation

The Task Force emerged from collaborations among professional bodies including the American College of Cardiology, American Heart Association, and specialty groups like the Heart Rhythm Society, American Society of Echocardiography, and Association of Black Cardiologists. Early influences included guideline initiatives from organizations such as the World Health Organization, National Heart, Lung, and Blood Institute, and seminal clinical trials originating at centers like Framingham Heart Study and Duke University Medical Center. Key figures in its evolution have worked alongside leaders from American Medical Association, Royal College of Physicians, and regulatory agencies such as the Food and Drug Administration and Centers for Medicare & Medicaid Services.

Purpose and scope

The Task Force issues consensus documents, guideline updates, and performance measures addressing conditions ranging from acute coronary syndrome and heart failure to valvular heart disease and cardiac arrhythmia. Partners span subspecialty societies including Society of Thoracic Surgeons, American College of Chest Physicians, and American Academy of Neurology when multidisciplinary input is required for conditions like stroke and pulmonary embolism. The scope covers diagnostic pathways, therapeutic interventions, and preventive strategies influenced by landmark trials such as SPRINT, COURAGE, PARTNER trial, and epidemiologic studies like Nurses' Health Study.

Guideline development process

Development typically begins with task selection involving stakeholders like American Board of Internal Medicine, payers such as Blue Cross Blue Shield Association, and federal entities including Agency for Healthcare Research and Quality. Writing committees include clinicians from institutions like University of Pennsylvania Health System and Yale School of Medicine, methodologists from groups such as the Institute of Medicine (now National Academy of Medicine), and representatives from subspecialties including interventional cardiology and cardiac surgery. Drafts undergo peer review by organizations such as the European Society of Cardiology, patient groups like American Stroke Association, and journal reviewers from publications such as Journal of the American College of Cardiology and Circulation.

Methodology and evidence grading

The Task Force adopted systematic review methods influenced by standards from Cochrane Collaboration, GRADE Working Group, and recommendations from the U.S. Preventive Services Task Force. Evidence grading links randomized trials from centers like Vanderbilt University Medical Center and observational registries such as Get With The Guidelines to recommendation strength statements used by policymakers including Centers for Disease Control and Prevention and professional credentialing bodies like American Board of Internal Medicine. Conflict of interest policies reference guidance from entities such as the World Medical Association and National Academy of Medicine.

Major guideline publications

Major outputs include guidelines on management of hypertension informed by trials like ALLHAT and ACCORD, recommendations for antiplatelet therapy after percutaneous coronary intervention referencing results from TRITON-TIMI 38 and PLATO, heart failure guidance incorporating data from PARADIGM-HF and SOLVD, valvular disease guidance influenced by the PARTNER and CoreValve studies, and atrial fibrillation guidance referencing AFFIRM and ROCKET AF. These publications are disseminated through journals such as Circulation, Journal of the American College of Cardiology, and education platforms at conferences including American College of Cardiology Annual Scientific Session and American Heart Association Scientific Sessions.

Implementation and impact

Implementation efforts partner with health systems like Kaiser Permanente, quality collaboratives such as Institute for Healthcare Improvement, and registries including STS National Database and American College of Cardiology National Cardiovascular Data Registry. Impact is measurable in performance metrics tracked by Centers for Medicare & Medicaid Services programs, quality improvement initiatives at Veterans Health Administration, and international adoption by societies like the European Society of Cardiology and Canadian Cardiovascular Society. Educational impact extends to trainees at Brigham and Women's Hospital, fellows from University of California, San Francisco, and continuing medical education providers such as American Medical Association.

Criticism and controversies

Critiques have focused on conflicts involving industry relationships with companies such as Medtronic, Boston Scientific, and Johnson & Johnson and debates paralleling controversies seen in other guideline-producing bodies like the U.S. Preventive Services Task Force. Methodological critiques echo discussions in works by Institute of Medicine panels and commentators from journals including The New England Journal of Medicine and BMJ. Debates have occurred over thresholds influenced by trials such as SPRINT and cost-effectiveness discussions involving payers like Centers for Medicare & Medicaid Services and private insurers, while legal and policy implications have drawn attention from institutions such as the American Civil Liberties Union and state legislatures.

Category:Cardiology